CA2598239A1 — Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
Assigned to Abraxis Bioscience LLC · Expires 2006-08-24 · 20y expired
What this patent protects
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a nanoparticle composition (such as a nonparticle composition of a taxane), a…
USPTO Abstract
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a nanoparticle composition (such as a nonparticle composition of a taxane), and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug (such as a taxane) in a nanoparticle composition based on a metronomic dosing regime.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.